Ocugen Book Value 2011-2026 | OCGN

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Ocugen

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
29.6 M	40.6 M	74 M	95.8 M	21.6 M	11 M	-458 K	-11.3 M	13.6 M	28.2 M	54.2 M	-75.6 M	-19.7 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
95.8 M	-75.6 M	20.1 M

Quarterly Book Value Ocugen

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
3.53 M	3.05 M	15.9 M	29.6 M	40.6 M	16.9 M	30.3 M	40.6 M	58.4 M	70.3 M	75.8 M	84.1 M	95.3 M	-	131 M	95.8 M	107 M	116 M	46.5 M	21.6 M	21.6 M	21.6 M	21.6 M	11 M	11 M	11 M	11 M	-12.7 M	-12.7 M	-458 K	-458 K	-11.3 M	-11.3 M	-11.3 M	-11.3 M	13.6 M	13.6 M	13.6 M	13.6 M	28.2 M	28.2 M	28.2 M	28.2 M	54.2 M	54.2 M	54.2 M	54.2 M	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
131 M	-12.7 M	32.7 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Apellis Pharmaceuticals APLS	370 M	$ 20.29	-1.98 %	$ 2.56 B	USA
Aptorum Group Limited APM	11.8 M	$ 0.8	-5.3 %	$ 4.36 M	China
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Axsome Therapeutics AXSM	88.3 M	$ 166.0	-0.23 %	$ 8.26 B	USA
AbCellera Biologics ABCL	967 M	$ 3.74	-2.23 %	$ 1.12 B	Canada
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
Burford Capital Limited BUR	1.66 B	$ 8.59	-1.66 %	$ 1.4 B	Britain
Certara CERT	1.06 B	$ 7.22	2.34 %	$ 1.16 B	USA
Catalyst Pharmaceuticals CPRX	954 M	$ 23.78	-0.42 %	$ 2.91 B	USA
Corvus Pharmaceuticals CRVS	38.7 M	$ 18.17	1.57 %	$ 873 M	USA
Adverum Biotechnologies ADVM	70.7 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
ARCA biopharma ABIO	382 M	-	1052.0 %	$ 415 M	USA
Eton Pharmaceuticals ETON	15.5 M	$ 17.9	-1.38 %	$ 459 M	USA
Exelixis EXEL	2.16 B	$ 40.5	-1.29 %	$ 11 B	USA
Acer Therapeutics ACER	-16.8 M	-	2.71 %	$ 14 M	USA
Alpine Immune Sciences ALPN	179 M	-	-	$ 2.17 B	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Galectin Therapeutics GALT	-103 M	$ 2.89	-5.56 %	$ 180 M	USA
Capricor Therapeutics CAPR	22.6 M	$ 26.3	-2.08 %	$ 704 M	USA
Acasti Pharma ACST	66.6 M	-	4.01 %	$ 150 M	Canada
Codexis CDXS	66.9 M	$ 1.02	-0.33 %	$ 74.9 M	USA
Galapagos NV GLPG	2.9 B	$ 33.13	-2.82 %	$ 2.69 B	Belgium
Greenwich LifeSciences GLSI	2.53 M	$ 27.88	1.79 %	$ 363 M	USA
Galecto GLTO	32.3 M	$ 29.63	-1.41 %	$ 787 M	Danmark
Genmab A/S GMAB	19.1 B	$ 27.66	-6.71 %	$ 17.7 B	Danmark
Halozyme Therapeutics HALO	48.8 M	$ 68.58	-1.82 %	$ 8.22 B	USA
CureVac N.V. CVAC	688 M	-	-	$ 867 M	Germany
Aeterna Zentaris AEZS	13.2 M	-	5.93 %	$ 314 M	Canada
Hoth Therapeutics HOTH	6.88 M	$ 1.0	-1.47 %	$ 6.38 M	USA
AgeX Therapeutics AGE	5.36 M	-	-10.17 %	$ 12.2 K	USA
Harmony Biosciences Holdings HRMY	870 M	$ 28.32	-2.01 %	$ 1.63 B	USA
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
ImmuCell Corporation ICCC	27.5 M	$ 6.3	-3.67 %	$ 51.5 M	USA
AIkido Pharma AIKI	39.9 M	-	1.93 %	$ 17.4 M	USA
Agenus AGEN	314 M	$ 3.27	-2.1 %	$ 1.17 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
Agios Pharmaceuticals AGIO	1.19 B	$ 28.57	-2.16 %	$ 1.66 B	USA
Immuron Limited IMRN	23.2 M	$ 0.75	-0.69 %	$ 6.46 M	Australia
Immunic IMUX	-6.67 M	$ 1.13	6.61 %	$ 176 M	USA
Immunovant IMVT	707 M	$ 27.09	-2.38 %	$ 4.11 B	USA
Inhibrx INBX	43.5 M	$ 76.39	-1.42 %	$ 3.6 B	USA
InMed Pharmaceuticals INM	12.1 M	$ 0.8	-2.44 %	$ 1.96 M	Canada